Mark A. Kronenfeld, Director at Pacira Pharmaceuticals Inc (NASDAQ:PCRX) disclosed today the acquisition of 850 shares of common stock in the open market at a unit price of $90.48 on November 3, 2014. This is the first transaction reported by Mr. Kronenfeld this year, so far the only insider acquiring the company’s stock, and now directly owns a total of 1,850 shares. The transaction imitates Mr. Kronenfeld’s last year acquisition in the month of September.
Ken Griffin’s Citadel Investment Group is the largest shareholding institution (amongst those we track) at Pacira Pharmaceuticals Inc (NASDAQ:PCRX) with close to 31.7 million shares, valued at an estimate $118 million, after reporting no changes at the end of the second filling period of 2014.
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) is a United States-based pharmaceutical company developing non-opioid products for postsurgical pain control. Its products include EXPAREL, DepoCyt(e), and DepoDur.
Disclosure: The author, Jodor Jalit, holds no position in any stocks or funds mentioned.
Suggested Articles:
Most Expensive Medical Schools
Highest Paid Actors For A Movie
